Abivax (ABVX) Other Accumulated Expenses (2024 - 2026)
Abivax's Other Accumulated Expenses came in at $71.82 million for Q4 2025, up 36.9% from $52.47 million a year earlier.
Powered by 
Analysis
Abivax (ABVX) Other Accumulated Expenses (2024 - 2026) Analysis & Trends
At the end of FY2025, Abivax's Other Accumulated Expenses was $69.71 million, up 31.2% from FY2024.
- Going back by year, Other Accumulated Expenses was $53.14 million in FY2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn |
| 10 | Abivax | 7.09 Bn | 4.73 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 70.02 Mn |
| Dec 31, 2025 | 72.48 Mn |
| Dec 31, 2024 | 51.09 Mn |
API Access
Abivax Other Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=ABVX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-accumulated-expenses", "ticker": "ABVX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=ABVX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();